A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

ClinicalTrials.gov ID: NCT05336409

Public ClinicalTrials.gov record NCT05336409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

Study identification

NCT ID: NCT05336409
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Century Therapeutics, Inc.; Industry
Enrollment: 28 participants

Conditions and interventions

Conditions

Interventions

CNTY-101 Biological
IL-2 Biological
Lymphodepleting Chemotherapy Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 24, 2023 (Actual)
Primary completion: Jul 1, 2025 (Actual)
Completion: Jul 1, 2025 (Actual)
Last update posted: Dec 18, 2025

2023 – 2025

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	—
University of Southern California - Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
University of California San Diego, Moores Cancer Center	San Diego	California	92093	—
Medstar Georgetown University Hospital	Washington D.C.	District of Columbia	20007	—
University of Kentucky - Markey Cancer Center	Lexington	Kentucky	40536	—
University of Maryland Medical Center	Baltimore	Maryland	21201	—
Henry Ford Hospital	Detroit	Michigan	48202	—
Corewell Health	Grand Rapids	Michigan	49503	—
Levine Cancer Institute	Charlotte	North Carolina	28204	—
University of Cincinnati Medical Center	Cincinnati	Ohio	45229	—
Oncology Hematology Care, Inc-Kenwood	Cincinnati	Ohio	45236	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
UT Southwestern	Dallas	Texas	75390	—
Houston Methodist Research Institute	Houston	Texas	77030	—
Virginia Oncology Associates	Norfolk	Virginia	23502	—
Swedish Cancer Institute	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05336409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2025 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05336409 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →